Back to top
more

Opexa Therapeutics, Inc. (OPXA)

(Delayed Data from NSDQ)

$0.97 USD

0.97
305,245

-0.10 (-9.36%)

Updated Sep 20, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Acer Therapeutics Inc. [OPXA]

Reports for Purchase

Showing records 1 - 20 ( 34 total )

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

11/16/2015

Company Report

Pages: 15

Reiterating Speculative Buy with an adjusted 12-month price target of $6.50 per share based on a year-ahead discounted value of projected 2026 revenue per share.

Provider: Taglich Brothers, Inc.

Analyst: NOBLE J

Price: 50.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

10/08/2015

Company Report

Pages: 7

Adjusting price target to reflect split

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/10/2015

Company Report

Pages: 4

Maintain price target of $3.06

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 10.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

09/01/2015

Company Report

Pages: 15

Initiating as Speculative Buy with a 12-month price target of $2.60 per share based on a year-ahead value of projected 2026 revenue per share.

Provider: Taglich Brothers, Inc.

Analyst: NOBILE J

Price: 50.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/27/2015

Company Report

Pages: 17

Initiate coverage with a price target of $3.06

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 50.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/11/2015

Daily Note

Pages: 4

Discontinuation of Coverage of the Biotech Sector

Provider: Brinson Patrick Securities Corporation

Price: 10.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/30/2015

Company Report

Pages: 7

Financing with Existing Shareholders Lifts Financial Overhang

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/10/2014

Company Report

Pages: 7

Targeting an Ultra-Orphan Disease

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

08/19/2014

Company Report

Pages: 6

2Q?14 EPS; Remains on Track with New Indication

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/19/2014

Company Report

Pages: 8

Reports 1Q?14 EPS; Abili-T Completely Enrolled

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/05/2014

Company Report

Pages: 8

Reception at ANN Ahead of Major Milestone

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/24/2014

Company Report

Pages: 28

Initiating coverage with a Market Outperform rating and a $6.00 one-year price target.

Provider: BRINSON PATRICK SECURITIES CORPORATION

Price: 75.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/24/2014

Company Report

Pages: 28

Initiating coverage with a Market Outperform rating and a $6.00 one-year price target.

Provider: BRINSON PATRICK SECURITIES CORPORATION

Price: 75.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

07/17/2012

Company Report

Pages: 3

We are terminating coverage due to the departure from the firm of covering analyst, Elemer Piros

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

06/29/2012

Company Report

Pages: 3

We are placing Opexa Therapeutics under review due to the departure from the firm of covering analyst

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/20/2012

Industry Report

Pages: 4

MONTHLY PORTFOLIO UPDATE

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

04/02/2012

Industry Report

Pages: 4

MONTHLY PORTFOLIO UPDATE

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/18/2011

Industry Report

Pages: 18

MONTHLY PORTFOLIO UPDATE - ELEMER PIROS

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 50.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/06/2011

Industry Report

Pages: 18

MONTHLY PORTFOLIO UPDATE- ELEMER PIROS

Provider: RODMAN & RENSHAW, CO.

Analyst: PIROS E

Price: 50.00

Research Provided by a Third Party

Company: Acer Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/17/2011

Industry Report

Pages: 18

MONTHLY PORTFOLIO UPDATE

Provider: RODMAN & RENSHAW, CO.

Price: 50.00

Research Provided by a Third Party
// eof